Hope to see you in Chicago for #BIO2013

We'll be in Chicago next week for BIO's International Convention. Here are a few things on our agenda--hope to see you there!

  • Only a handful of seats left for our "Welcome to the R&D Revolution" executive breakfast, and you can register here. The event is on Tuesday, 4/23 from 7:00 a.m. to 8:30 a.m., located conveniently next to the convention at Hyatt Regency McCormick Place.

    John Carroll is moderating the panel featuring Briggs Morrison, EVP, Global Medicines Development, AstraZeneca ($AZN); Martin Fitchet, chief operating officer and heart disease expert for the global Johnson & Johnson ($JNJ) Pharmaceutical Research & Development organization; José-Carlos Gutiérrez-Ramos, SVP, head of BioTherapeutics R&D, Pfizer ($PFE); and Perry Nisen, SVP of Science and Innovation, GlaxoSmithKline ($GSK).

  • Ryan McBride hosts a panel, "Partnering in the Cloud - Can Pharma Drive Innovation through Big Data?" from 2:00 p.m. to 3:30 p.m on Tuesday at the What's Your BIO Theatre on the show floor. Find more info here.

    Ryan will be talking to Marc Berger, Vice President, Real World Data and Analytics; Gunaretnam Rajagopal VP & CIO, Research, Bioinformatics & External Innovation at Janssen Pharmaceutical; Yury Rozenman, head of marketing at Global Commerce, British Telecom Services; and Kenneth E. Russell, Ph.D., Director, Advanced Services & Strategic Initiatives at CISCO.

  • Right after Ryan's panel, have a drink on us and meet the team at the FierceBiotech IT meetup from 3:30 p.m. to 4:00 p.m., in the Bio-IT Zone on the show floor.

  • And on Monday, 4/22 from 4:00 p.m. to 6:30 p.m., we'll be at Women In Bio's annual celebration featuring a keynote address by Jill Milne, CEO of Catabasis Pharmaceuticals. Register here for the event.

    I'll also be there to kick things off with a short presentation on FierceBiotech's annual "Women in Biotech" report, highlighting the women we've featured previously. A few of them will be at the event, including Deborah Dunsire, CEO of Millennium Pharmaceuticals; Deborah Keller, EVP and Group President, R&D laboratories at Covance; Maxine Gowen, President and CEO of Trevena; Susan Molineaux, President and CEO of Calithera Biosciences; and Andrea Pfeifer, CEO of AC Immune.

-- Jennifer Levin (email | Twitter)

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.